Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewGenIvf (NIVF) Cash & Equivalents (2022 - 2025)

NewGenIvf (NIVF) has disclosed Cash & Equivalents for 4 consecutive years, with $758621.0 as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 65.73% to $758621.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $758621.0 through Dec 2025, up 65.73% year-over-year, with the annual reading at $758621.0 for FY2025, 65.73% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $758621.0 at NewGenIvf, up from $457740.0 in the prior quarter.
  • The five-year high for Cash & Equivalents was $758621.0 in Q4 2025, with the low at $27556.0 in Q4 2022.
  • Average Cash & Equivalents over 4 years is $324505.2, with a median of $255922.0 recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 746.04% in 2024, then skyrocketed 65.73% in 2025.
  • Over 4 years, Cash & Equivalents stood at $27556.0 in 2022, then soared by 96.34% to $54104.0 in 2023, then soared by 746.04% to $457740.0 in 2024, then soared by 65.73% to $758621.0 in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $758621.0, $457740.0, and $54104.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.